Axsome Therapeutics (AXSM) Operating Expenses (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Operating Expenses data on file, last reported at $254.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 42.65% year-over-year to $254.6 million; the trailing twelve-month figure through Mar 2026 stood at $881.4 million (up 25.48% YoY), and the FY2025 full-year result was $805.3 million, up 20.86% from the prior year.
• Operating Expenses improved to $254.6 million in Q1 2026, from $223.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $254.6 million in Q1 2026 to a low of $38.3 million in Q1 2022.
• A 5-year average of $144.6 million and a median of $165.2 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 163.65% in 2023 and gained 12.71% in 2024, its largest moves.
• Tracing AXSM's Operating Expenses over 5 years: stood at $84.3 million in 2022, then soared by 101.45% to $169.8 million in 2023, then climbed by 12.71% to $191.4 million in 2024, then increased by 16.5% to $223.0 million in 2025, then advanced by 14.17% to $254.6 million in 2026.
• Business Quant data shows AXSM's Operating Expenses at $254.6 million in Q1 2026, $223.0 million in Q4 2025, and $217.1 million in Q3 2025.